OpenScience.ink

2 weeks ago • Molecular metabolism

Semaglutide’s effects on male and female rat reproductive systems compared to equal calorie reductionBeyond Weight Loss: Disentangling the Direct Effects of Semaglutide vs Equivalent Calorie Restriction on Reproductive Systems of Male and Female Rats.

🥉 Top 5% JournalArticle

2 weeks ago • Science (New York, N.Y.)

Expected and unexpected effects of widely prescribing GLP-1 medicines(Un)intended consequences of mass-prescribing GLP-1s.

Editorial

2 weeks ago • Diabetes, obesity & metabolism

Safety concerns and medication risks of GLP-1 therapies for diabetes and obesity from multiple monitoring sourcesPostmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.

Article

2 weeks ago • Ophthalmology. Retina

Use of GLP-1 Drugs and Risk of Sudden Optic Nerve Damage in People with Type 2 DiabetesGLP1-RA Use and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes.

🥉 Top 5% JournalArticle

2 weeks ago • Endocrinology

IL-22 raises hormone-producing gut cells through STAT3 in human stem cell-based intestinal tissueIL-22 Increases Proglucagon-expressing Enteroendocrine Cells via STAT3 in Human iPSC-derived Intestinal Epithelium.

🎖️ Top 10% JournalArticle

2 weeks ago • JAMA otolaryngology-- head & neck surgery

Glucagon-Like Peptide-1 Receptor Agonists and Their Potential Role in Obstructive Sleep ApneaGlucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.

🎖️ Top 10% JournalArticle

2 weeks ago • Nature

Semaglutide treatment later in life slows aging and extends lifespan in female miceLate-life semaglutide treatment slows ageing and extends lifespan in female mice.

Article

2 weeks ago • The Orthopedic clinics of North America

Use of Glucagon-like Peptide-1 Receptor Agonists May Lower Disease Activity and Slow Progression in Osteoarthritis and Inflammatory ArthritisGlucagon-like Peptide-1 Receptor Agonist Use May Reduce Disease Activity and Progression in Osteoarthritis and Inflammatory Arthritis.

📖 Top 30% JournalArticle

2 weeks ago • Current medical research and opinion

Preventing Type 2 Diabetes in Obese People: From Insulin Resistance to Using Incretin Receptor TreatmentsFrom insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals.

Article

2 weeks ago • Respiratory medicine

Lung response to diabetes treatment using GLP-1 receptor agonists in adults with cystic fibrosis: factors linked to better lung functionPulmonary response to glucagon-like peptide-1 receptor agonist therapy in adults with cystic fibrosis-related diabetes: factors associated with improvement in FEV1.

📖 Top 20% JournalArticle

2 weeks ago • Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

Changes in methods used for weight loss before body shaping surgeryTrends in preoperative weight loss modalities among patients receiving body contouring surgery.

📖 Top 20% JournalArticle

2 weeks ago • Journal of clinical neurology (Seoul, Korea)

Use of Glucagon-Like Peptide-1 Receptor Agonists After Mini-Stroke and Its Link to Risk of Later Stroke and DeathEffects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and Mortality.

📖 Top 20% JournalArticle

2 weeks ago • JMIR diabetes

Social Media Talk about Diabetes Medicines and the Popularity of GLP-1 TreatmentsSocial Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis.

📖 Top 20% JournalArticle

2 weeks ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

How Gut Bacteria and Body Chemicals Relate to Obesity and Treatments at Different AgesMicrobiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan.

Article

2 weeks ago • Cardiovascular diabetology. Endocrinology reports

Heart and metabolism effects of once-weekly IcoSema in adults with type 2 diabetesCardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.

Article

2 weeks ago • JAMA psychiatry

Use of GLP-1 Receptor Agonist Medications in People With and Without Serious Mental IllnessGLP-1 Receptor Agonist Prescriptions Among People With and Without Serious Mental Illness.

🥇 Top 1% JournalArticle

2 weeks ago • Diabetes, obesity & metabolism

Incretin-Based Treatments for Heart and Metabolic Health: How They Work, Their Effects, and Best Uses for Different Patient TypesIncretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.

Article

2 weeks ago • Obesity science & practice

Patients' experiences of continuing GLP-1 receptor agonist treatmentPatient-Reported Continuity of GLP-1 Receptor Agonist Therapy.

📖 Top 30% JournalArticle

2 weeks ago • npj metabolic health and disease

Higher semaglutide doses linked to fewer mental health problems regardless of weight lossHigher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.

Article

2 weeks ago • Gut and liver

Gastroesophageal Reflux Disease Linked to GLP-1 Receptor Agonists: A Multi-Country Drug Safety AnalysisMulti-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.

🎖️ Top 10% JournalArticle

2 weeks ago • Diabetes care

Short-term risk of serious stomach problems with different opioids in patients using diabetes drugsComparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists.

Article

2 weeks ago • Clinics in dermatology

GLP-1 Receptor Agonists as Treatments for Skin Conditions Linked to Other DiseasesWhere the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities.

📖 Top 50% JournalArticle

2 weeks ago • Frontiers in pharmacology

How Tirzepatide may help treat obesity without diabetes: underlying actions, clinical results, and future possibilitiesTirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions.

📖 Top 20% JournalArticle

2 weeks ago • Indian journal of pharmacology

Current and new drug treatments for obesityPharmacological management of obesity: Current landscape and emerging therapies.

📖 Top 50% JournalArticle

2 weeks ago • Journal of medical Internet research

Digital Use and Factors Linked to Staying on Semaglutide and Losing Weight in Severe Obesity Over 48 WeeksDigital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study.

🥉 Top 5% JournalObservational Study

2 weeks ago • Kidney research and clinical practice

Incretin-based treatments for diabetic kidney disease and their role in improving heart, kidney, and metabolism healthIncretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.

📖 Top 20% JournalArticle

2 weeks ago • Clinical spine surgery

Use of Glucagon-Like Peptide-1 Drugs and Vertebral Fracture Risk in Women Over 50 with OsteoporosisInvestigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis: A Propensity-Matched Analysis.

📖 Top 30% JournalArticle

2 weeks ago • Journal of Yeungnam medical science

Muscle loss linked to metabolism and mitochondria during incretin-based treatment: causes and new therapy ideasMetabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies.

📖 Top 50% JournalArticle

2 weeks ago • Frontiers in endocrinology

Effectiveness of diabetes drugs and aerobic exercise for moderate-to-severe sleep apnea in overweight or obese patientsEfficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysis.

🎖️ Top 10% JournalSystematic Review

2 weeks ago • Diabetes, obesity & metabolism

Blood Sugar Changes After Stopping Semaglutide in Adults with Type 1 Diabetes Using Automated Insulin DeliveryGlycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.

Article

← prevpage 8 of 14next →

Latest GLP-1 Therapies Research Papers